DK0964697T3 - Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen - Google Patents

Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen

Info

Publication number
DK0964697T3
DK0964697T3 DK97948102T DK97948102T DK0964697T3 DK 0964697 T3 DK0964697 T3 DK 0964697T3 DK 97948102 T DK97948102 T DK 97948102T DK 97948102 T DK97948102 T DK 97948102T DK 0964697 T3 DK0964697 T3 DK 0964697T3
Authority
DK
Denmark
Prior art keywords
antigens
rma
gene
expressed
cells transfected
Prior art date
Application number
DK97948102T
Other languages
Danish (da)
English (en)
Inventor
Elisabeth Wolpert
Klas Kaerre
Max Pettersson
Johan Sandberg
Original Assignee
Accuro Immunology Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accuro Immunology Ab filed Critical Accuro Immunology Ab
Application granted granted Critical
Publication of DK0964697T3 publication Critical patent/DK0964697T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK97948102T 1996-12-12 1997-12-12 Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen DK0964697T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604581A SE9604581D0 (sv) 1996-12-12 1996-12-12 An agent against cancer and virus infections
PCT/SE1997/002094 WO1998025645A1 (en) 1996-12-12 1997-12-12 Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene

Publications (1)

Publication Number Publication Date
DK0964697T3 true DK0964697T3 (da) 2003-04-22

Family

ID=20404956

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97948102T DK0964697T3 (da) 1996-12-12 1997-12-12 Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen

Country Status (12)

Country Link
US (1) US20030087846A1 (de)
EP (1) EP0964697B1 (de)
JP (1) JP2001517208A (de)
AT (1) ATE234628T1 (de)
AU (1) AU5423898A (de)
CA (1) CA2274837A1 (de)
DE (1) DE69720065T2 (de)
DK (1) DK0964697T3 (de)
ES (1) ES2193408T3 (de)
PT (1) PT964697E (de)
SE (1) SE9604581D0 (de)
WO (1) WO1998025645A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022573A2 (en) * 2000-09-15 2002-03-21 The Scripps Research Institute Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
EP1994406A1 (de) * 2006-03-16 2008-11-26 Leiden University Medical Center Verfahren zur identifizierung von t-zellepitopen in verbindung mit gestörter peptidprozessierung und anwendung der identifizierten epitope
WO2008069663A1 (en) 2006-12-07 2008-06-12 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
WO2009008713A1 (en) * 2007-07-09 2009-01-15 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce Tap-inhibitors from old world primate 1-herpesviruses and their use
FR2931485B1 (fr) * 2008-05-23 2011-06-17 Centre Nat Rech Scient Vaccin antitumoral comprenant des cellules tumorales modifiees
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
EP4096787A4 (de) * 2020-01-29 2024-05-29 University of Miami Impfstoff gegen in pathogeninfizierten zellen induzierte antigene
CN111979243B (zh) * 2020-08-24 2023-05-23 大连大学 利用CRISPR/Cas9系统构建TAP基因缺失的猪T2细胞的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2024458A1 (en) * 1970-05-20 1971-12-02 Hartmann geb. Ungewitter, Philippine, Dr., 8000 München Tumour antigen - modified and potentiated by irradiation
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
JPH08501280A (ja) * 1992-05-26 1996-02-13 リュクスウニヴェルシテート レイデン ヒトＴ細胞応答誘発組成物に用いるためのヒトｐ５３タンパク質のペプチドおよびヒトｐ５３タンパク質特異的細胞毒性Ｔリンパ球
ES2197147T3 (es) * 1992-10-02 2004-01-01 Bristol-Myers Squibb Company Inhibicion del crecimiento de celulas tumorales mediante la administracion de celulas transfectadas b7.
US5750398A (en) * 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
US6361770B1 (en) * 1994-09-23 2002-03-26 University Of British Columbia Method of enhancing expression of MHC class I molecules bearing endogenous peptides
EP0863913A4 (de) * 1995-08-21 2001-04-11 Univ Duke Methode zur erhölung der dichte eines antigens auf antigen-präsentierenden zellen

Also Published As

Publication number Publication date
EP0964697B1 (de) 2003-03-19
CA2274837A1 (en) 1998-06-18
EP0964697A1 (de) 1999-12-22
ES2193408T3 (es) 2003-11-01
WO1998025645A1 (en) 1998-06-18
ATE234628T1 (de) 2003-04-15
DE69720065D1 (de) 2003-04-24
JP2001517208A (ja) 2001-10-02
DE69720065T2 (de) 2003-12-04
SE9604581D0 (sv) 1996-12-12
PT964697E (pt) 2003-07-31
AU5423898A (en) 1998-07-03
US20030087846A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
DK0851927T3 (da) Forbindelser til immunterapi og diagnosticering af tuberkulose
DK0979284T4 (da) Reagenser til vaccination, som fremkalder en CD8 T-celleimmunreaktion
DK0724432T3 (da) Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
DK0964697T3 (da) Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen
NO20075900L (no) Forbindelser for immunterapi og diagnose av tuberkulose og metoder for deres anvendelse
DK1276896T3 (da) Epitop-synkronisering i antigen-præsenterende celler
CY1106350T1 (el) Εμβολιο φυματιωσης
BR9814204A (pt) "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
ATE386049T1 (de) Epstein-barr virus type b ctl epitopen
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
NO20042124L (no) Thymosinforsterkning ved genetisk immunisering
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους